My husband won't want to pause as he can feel the Cancer is on the move in his body. We spent 3 months on...

I want to acknowledge how stressful this situation is—dealing with cancer progression, treatment side effects, an oncologist retiring, and uncertainty about next steps. Your husband's concern about the cancer moving is understandable given the PET scan showing progression. Let me help clarify what these results mean and what questions to bring to your next oncologist.

WHAT YOUR HUSBAND'S TEST RESULTS SHOW

The PET Scan Finding: The FDG-avid lesions (metabolically active cancer spots) throughout his chest, abdomen, and bones indicate the cancer is actively growing and spreading. This is why your husband can sense something is happening—the imaging confirms disease progression.

The Genomic Results—This Is Important: Your husband's tumor has several significant findings:

• HRD signature POSITIVE — This is the key finding regarding your PARP inhibitor question
• BRCA1 mutation (Q1756fs*74) — A pathogenic BRCA1 mutation
• Microsatellite stable (not MSI-high)
• MTAP loss, CDKN2A/2B loss — Additional tumor suppressors lost
• Tumor mutational burden: 6 mutations/megabase — Moderate

WHY YOUR ONCOLOGIST MAY HAVE SAID "NO" TO PARP—AND WHY THIS DESERVES RECONSIDERATION

Here's the clinical reasoning doctors use with PARP inhibitors:

Traditional PARP Eligibility (Why she may have initially declined):

• PARP inhibitors like olaparib (Lynparza) are FDA-approved for BRCA1/2-mutated pancreatic cancer, but duodenal adenocarcinoma is a different cancer type
• Standard guidelines (NCCN) typically reserve PARP inhibitors for specific cancer types with BRCA mutations
• Your husband's microsatellite stable status means he's not MSI-high (which opens different immunotherapy doors)

BUT—Here's What Changed:

• Your husband has HRD signature positive PLUS BRCA1 mutation
• Recent evidence and clinical experience suggest HRD-positive tumors may respond to PARP inhibitors even outside traditional indications
• This is an area where off-label use becomes a legitimate discussion with an oncologist who specializes in rare GI cancers or precision oncology

WHAT HAPPENED WITH PANITUMUMAB (And Why It Matters)

Panitumumab targets EGFR. The fact it caused severe side effects without benefit suggests:

• His tumor may not be EGFR-dependent
• His genomic profile (BRCA1 mutation, HRD signature) points toward DNA repair deficiency as the vulnerability, NOT growth factor signaling

This actually strengthens the case for exploring PARP inhibitors or other DNA repair-targeting approaches.

YOUR NEXT STEPS—CRITICAL QUESTIONS FOR THE NEW ONCOLOGIST

When you meet with your new oncologist (after your current one retires), bring these specific questions:

1. "Given my husband's HRD-positive signature AND BRCA1 mutation, would olaparib (Lynparza) or another PARP inhibitor be appropriate to consider, even though duodenal cancer isn't the typical indication? What would you need to explore this?"

2. "His tumor showed progression on Panitumumab. Given his genomic profile, what would you recommend as the next line of treatment? Are there clinical trials for HRD-positive GI cancers?"

3. "He has MTAP loss and CDKN2A/2B loss. Are there targeted therapies or combinations that address these specific mutations?"

4. "Should we consider referral to a specialized center (like a major cancer center or precision oncology program) given the complexity of his case and the progression?"

5. "What's your experience with PARP inhibitors in duodenal adenocarcinoma, and would you be willing to discuss this with a GI oncology specialist if you're uncertain?"

THE REFERRAL/PROVINCIAL ISSUE

Your current oncologist saying "no doctor will see you out of province" is not accurate in most healthcare systems. Here's what you can do:

• Request a formal referral to a major cancer center (academic medical center, NCI-designated cancer center, or specialized GI oncology program)
• Ask specifically for a second opinion on the PARP inhibitor question—this is standard practice
• Contact the cancer center directly if the referral is delayed; many have patient navigation services
• Mention the BRCA1 mutation and HRD signature when requesting the referral—this often expedites appointments

WHAT THE EVIDENCE SAYS

According to NCCN Guidelines for Pancreatic Cancer and emerging data on HRD-positive tumors:

• HRD signature positivity is increasingly recognized as a treatment predictor across cancer types
• PARP inhibitors show activity in HRD-positive cancers beyond traditional indications
• American Society of Clinical Oncology (ASCO) recognizes that genomic findings can guide off-label treatment discussions

For duodenal adenocarcinoma specifically, the National Cancer Institute and specialized GI oncology programs are exploring precision approaches based on genomic profiles like your husband's.

THE BIGGER PICTURE

Your husband's intuition about disease progression is validated by the imaging. The good news: his genomic profile reveals specific vulnerabilities (HRD, BRCA1 mutation) that suggest targeted approaches beyond standard chemotherapy. The challenge is finding an oncologist willing to explore these options.

Don't accept "no" on PARP inhibitors without a detailed explanation. A precision oncology specialist or GI cancer specialist should review this case.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.